Independent PatientView Survey

Now Launched: Corporate Reputation of Pharma 2024/5

Survey starts December 10th 2024, finishing 18th March 2025.

■ Two decades of experience
■ Now in it’s 14th year
■ Database of 40,000 patient groups worldwide
■ Survey and report available in 23 languages
■ Analyses based on geographic regions and therapy areas
■ Feedback from 2400+ patient groups in 2024; a record number
■ An extensive evidence base of patient-group views
■ 46 companies involved

[Access the survey questionnaires for 2024/2025 here]

Pharmaceutical companies included in PatientView’s Corporate Reputation of Pharma 2024/2025:

New companies for 2024/2025 included in bold*:

AbbVie • Amgen / including Horizon • Alnylam Pharmaceuticals • Angelini Pharma • Astellas Pharma • AstraZeneca / including Alexion • Bayer • Biogen • BioMarin • Boehringer Ingelheim • Bristol Myers Squibb • Chiesi / including Amyrt • Crinetics Pharmaceuticals • CSL Behring • Daiichi Sankyo • Eisai • Esteve Healthcare • Eli Lilly • Exelixis • Gilead Sciences / including Kite Pharma • GSK • Incyte • Ipsen • Johnson & Johnson Innovative Medicine (formerly Janssen) • Jazz Pharmaceuticals • LEO Pharma • Lundbeck • Merck KGaA/EMD Serono • Merck & Co/MSD • Novartis • Novo Nordisk • Otsuka • Pfizer • PTC Therapeutics • Recordati • Regeneron Pharmaceuticals • Roche/Genentech/Chugai • Sanofi • Sarepta Therapeutics • Servier • Sobi • Takeda • UCB • Vertex • Viatris • ViiV Healthcare

[Find out more on PatientView’s methodology for this survey]

[Find out more about Corporate Reputation of Pharma from a Patient Perspective: Types of Data Analysed]

Up